Phase 1 HIV trials recruiting now

All HIV trials, every phase

Other phases for HIV

Phase 1 HIV trials

• A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
  NCT07392372 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 6 locations
• A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
  NCT07698600 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
  NCT07390955 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 11 locations
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
  NCT06724640 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders
  NCT07579741 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
  NCT07275606 · Phase: Phase 1, Phase 2 · Ages: Up to 10 Days · Sex: All (male and female) · 1 location
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
  NCT05418868 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
  NCT07525544 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.
  NCT06617091 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 3 locations
• A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
  NCT07569029 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 19 locations
• Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
  NCT04941274 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
  NCT05487807 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
  NCT05668026 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• CAR-T Cells for HIV Infection
  NCT04648046 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Cabotegravir-Hormone PK/PD Interactions for HIV Prevention
  NCT07672717 · Phase: Phase 1 · Ages: 19 Years and older · Sex: All (male and female) · 1 location
• Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
  NCT06665646 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 9 locations
• Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health
  NCT06796686 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 6 locations
• Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV
  NCT07390474 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 7 locations
• Dasatinib for HIV-1 Reservoir Reduction
  NCT07342491 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
  NCT05069688 · Phase: Phase 1 · Ages: 4 Weeks to 5 Years · Sex: All (male and female) · 1 location
• Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
  NCT06281834 · Phase: Phase 1 · Ages: 4 Weeks to 11 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)
  NCT07711223 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
  NCT06205056 · Phase: Phase 1 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 1 location
• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
  NCT06071767 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers
  NCT07349758 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
  NCT07433387 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• First Time in Human Study of Long Acting VH4524184 Formulations
  NCT06310551 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
  NCT07530198 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)
  NCT06513819 · Phase: Phase 1 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
  NCT05077527 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
  NCT07481175 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
  NCT06819176 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Lopinavir/Ritonavir in PLWH With High-Grade AIN
  NCT05334004 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
  NCT05187429 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
  NCT07636928 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
  NCT05939167 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
  NCT04303117 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
  NCT05674656 · Phase: Phase 1, Phase 2 · Ages: 6 Years to 12 Years · Sex: All (male and female) · 8 locations
• Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
  NCT05389423 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
  NCT04902443 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
  NCT06484335 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
  NCT05586581 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety Study of MucoCept-CVN
  NCT07181486 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: Female · 1 location
• Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
  NCT03878121 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
  NCT05580458 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety of Anal Curcumin
  NCT06626230 · Phase: Phase 1 · Ages: 30 Years and older · Sex: All (male and female) · 2 locations
• Study of GS-0415 and How It Works in People With HIV
  NCT07719491 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
  NCT07040319 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 45 Years · Sex: Female · 10 locations
• T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
  NCT06343311 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
  NCT03240328 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients
  NCT06880380 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• The Tatelo Plus Study
  NCT06508749 · Phase: Phase 1, Phase 2 · Ages: 24 Weeks to 25 Years · Sex: All (male and female) · 2 locations
• Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
  NCT05470491 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 120 Years · Sex: All (male and female) · 1 location
• Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
  NCT02140255 · Phase: Phase 1, Phase 2 · Ages: Up to 48 Hours · Sex: All (male and female) · 46 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.